Neuropace Inc (NPCE) - Net Assets
Based on the latest financial reports, Neuropace Inc (NPCE) has net assets worth $14.45 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($98.90 Million) and total liabilities ($84.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Neuropace Inc (NPCE) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.45 Million |
| % of Total Assets | 14.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -74.11% |
| 10-Year Change | N/A |
| Growth Volatility | 82.17 |
Neuropace Inc - Net Assets Trend (2019–2025)
This chart illustrates how Neuropace Inc's net assets have evolved over time, based on quarterly financial data. See NPCE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Neuropace Inc (2019–2025)
The table below shows the annual net assets of Neuropace Inc from 2019 to 2025. For live valuation and market cap data, see Neuropace Inc (NPCE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $19.03 Million | +137.50% |
| 2024-12-31 | $8.01 Million | -61.20% |
| 2023-12-31 | $20.65 Million | -40.61% |
| 2022-12-31 | $34.78 Million | -52.69% |
| 2021-12-31 | $73.50 Million | +149.72% |
| 2020-12-31 | $-147.83 Million | -14.29% |
| 2019-12-31 | $-129.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuropace Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18877400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.00K | 0.18% |
| Other Components | $571.41 Million | 3002.53% |
| Total Equity | $19.03 Million | 100.00% |
Neuropace Inc Competitors by Market Cap
The table below lists competitors of Neuropace Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Grandbuy Co Ltd
SHE:002187
|
$516.92 Million |
|
Andersen Group Inc.
NYSE:ANDG
|
$516.93 Million |
|
Zhejiang Tengen Electrics Co Ltd
SHG:605066
|
$517.03 Million |
|
Grenevia S.A.
WAR:GEA
|
$517.18 Million |
|
Yieh United Steel
TWO:9957
|
$516.81 Million |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
$516.78 Million |
|
H&R Century Union Corp
SHE:000892
|
$516.77 Million |
|
Nouveau Monde Graphite Inc
NYSE:NMG
|
$516.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuropace Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,013,000 to 19,031,000, a change of 11,018,000 (137.5%).
- Net loss of 21,465,000 reduced equity.
- Share repurchases of 49,546,000 reduced equity.
- New share issuances of 69,886,000 increased equity.
- Other factors increased equity by 12,143,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.46 Million | -112.79% |
| Share Repurchases | $49.55 Million | -260.34% |
| Share Issuances | $69.89 Million | +367.22% |
| Other Changes | $12.14 Million | +63.81% |
| Total Change | $- | 137.50% |
Book Value vs Market Value Analysis
This analysis compares Neuropace Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 26.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-11.65 | $15.16 | x |
| 2020-12-31 | $-13.31 | $15.16 | x |
| 2021-12-31 | $4.43 | $15.16 | x |
| 2022-12-31 | $1.41 | $15.16 | x |
| 2023-12-31 | $0.80 | $15.16 | x |
| 2024-12-31 | $0.28 | $15.16 | x |
| 2025-12-31 | $0.58 | $15.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuropace Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -112.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.47%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 5.55x
- Recent ROE (-112.79%) is above the historical average (-113.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -81.07% | 1.75x | 0.00x | $-17.04 Million |
| 2020 | 0.00% | -59.02% | 0.74x | 0.00x | $-9.49 Million |
| 2021 | -49.09% | -79.85% | 0.34x | 1.82x | $-43.43 Million |
| 2022 | -135.38% | -103.43% | 0.40x | 3.28x | $-50.56 Million |
| 2023 | -159.56% | -50.38% | 0.61x | 5.21x | $-35.02 Million |
| 2024 | -338.71% | -33.97% | 0.84x | 11.81x | $-27.94 Million |
| 2025 | -112.79% | -21.47% | 0.95x | 5.55x | $-23.37 Million |
Industry Comparison
This section compares Neuropace Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuropace Inc (NPCE) | $14.45 Million | 0.00% | 5.84x | $516.86 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more